Positron Emission Tomography (PET) PET is a functional imaging technique that has proven benefits in the management of Oncology patients. By detecting an increased utilisation of glucose in tumour tissue with the PET radiopharmaceutical 18Fluorodeoxyglucose (FDG), it is possible to image malignant tissue, often before it is visible with other techniques. In Oncology there are evidence-based roles for PET at many stages of the disease process, including initial diagnosis, staging, restaging and recurrence, evaluation of residual masses and the early functional assessment of disease response. State of the art PET imaging also incorporates CT image fusion from the same combined scanner allowing simultaneous display of anatomical and functional information to significantly enhance the diagnostic capacity of PET. Case Studies Case 1 A 44 year old female complained of right breast fullness and slight discomfort from an axillary nodule. In spite of negative mammograms a fine needle biopsy of the axillary node was performed that confirmed adenocarcinoma. The initial PET scan revealed the primary tumour and local lymphadenopathy. The patient completed four cycles of chemotherapy and returned for a follow-up PET scan that showed that the disease had responded to the chemotherapy. Case 2 A 54 year old female with a history of cervical cancer was scanned on a biograph™ PET/CT scanner for therapy planning. The combined PET/CT scan showed focal uptake in two pelvic sidewall nodes, not noted on a recent clinical CT. Also, a focus of uptake is noted in the para-aortic region (arrow). print these case studies